India Pricing Authority Chief Says List Is No Attempt To Vilify Industry
The chair of India’s National Pharmaceutical Pricing Authority has tried to clear the air around the regulator’s recent public notice that lists over 600 products suspected of having flouted price caps, telling Scrip the chances of error around the data used to verify compliance is low, though at least half a dozen companies on the list indicate they have complied with the regulator’s norms.
You may also be interested in...
Coronavirus Notebook: Fauci Calls For Restraint In Disclosing Early Data; Bipartisan Lawmakers Want Warp Speed Audit
Dispatches from a world turned upside down also include the conditional approval of remdesivir in South Korea.
Sun’s Q1 earnings were dented by provisions related to the generic pricing investigation settlement with the US Department of Justice of arm Taro, and the impact of pandemic-related lockdowns. Some clinic-administered products bore the brunt of lock-downs in parts of the US, though market share was unaffected.
High-profile experts including Anthony Fauci and Adrian Hill share views at the ICMR symposium on progressing safe COVID-19 vaccines backed by ethical trials executed with appropriate scientific rigor. Human challenge studies, "vaccine nationalism" and equitable access were among the key issues deliberated, while India committed to making its coronavirus vaccines and related capabilities available to the world.